ArticleBMC infectious diseases2026
Antifungal susceptibility, FKS1 gene expression, and virulence determinants of Candida albicans in pediatric and neonatal candidiasis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida albicans is a major cause of invasive fungal infections in pediatric patients, including subgroups of neonates and young infants, particularly in intensive care settings where premature and low birth weight infants are at high risk. Management is increasingly complicated by antifungal resistance, notably to echinocandins. Understanding basal FKS1 expression, antifungal susceptibility, and virulence traits in neonatal isolates, as a subgroup within pediatric patients, provides preliminary insights for clinical management.
methodsA cross-sectional study was conducted on pediatric patients with suspected fungal infections admitted to NICU, PICU, IICU, and other specialized wards of the Children’s Medical Center, Tehran, Iran. Clinical specimens were collected from multiple sources including urine catheters, blood, abscesses, bronchoalveolar lavage, and other body fluids. Of 62 Candida isolates recovered, 50 (80.6%) were identified as C. albicans. For detailed molecular, antifungal susceptibility, enzymatic virulence, and FKS1 expression analyses, 20 isolates from children under two years of age (7 newborns and 13 infants) were selected. Species identification was confirmed by ITS sequencing. Antifungal susceptibility testing followed CLSI M27-A4 documents with MICs determined based on 50% growth inhibition. Virulence was assessed via phospholipase and proteinase enzymatic activity, and FKS1 gene expression was measured using real-time PCR.
resultsAll 50 analyzed isolates were confirmed as C. albicans with > 99% ITS sequence identity. Phylogenetic analysis revealed strong genetic relatedness among isolates. Caspofungin and amphotericin B demonstrated the highest in vitro efficacy, with 44 isolates (88%) susceptible to caspofungin and 27 isolates (54%) susceptible to amphotericin B. Resistance to fluconazole and ketoconazole was observed in 28 (56%) and 33 (66%) isolates, respectively. Virulence profiling showed that a subset of pediatric isolates, including neonatal cases, exhibited strong phospholipase and proteinase activity, suggesting elevated pathogenic potential within this subgroup. FKS1 was detected in all isolates, with expression levels varying significantly; notably, two neonatal isolates showed higher basal FKS1 expression, potentially indicating early adaptive responses to echinocandin exposure despite phenotypic susceptibility. All subsequent analyses, including molecular and functional assays, explicitly indicate the number of isolates evaluated for each experiment, ensuring clarity and reproducibility.
conclusionThis study highlights the multifactorial pathogenicity of C. albicans in pediatric patients, with exploratory observations in neonates and young infants characterized by variable antifungal resistance and virulence factor expression. Variations in basal FKS1 expression are described as preliminary findings. These data underscore the value of integrating molecular diagnostics, antifungal susceptibility testing, and virulence profiling to guide therapy, without making unsupported claims about echinocandin tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.